Clinically, atezolizumab (anti-PD-L1) plus bevacizumab (anti-VEGF) significantly improved survival in advanced HCC, in part through dynamic modulation of TAN phenotypes (148). This evidence concerns the gene CD274 and hepatocellular carcinoma.